# Yanchuang Capital

> Yanchuang Capital is a VC fund in Chaoyang backing Biotechnology and Health Care. See 27 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Chaoyang, China
- Total investments: 27
- Last investment: Aug 2026
- Lead investor: 26%
- Last updated: Sep 2026
- Website: http://www.yccapital.cn/

Yanchuang Capital is a VC fund in Chaoyang focused on Biotechnology and Health Care. "Yan Chuang Capital", the full name of "Yanyuan Innovation Capital Group", was founded in June 2010, formerly known as "Yanyuan Capital Group". A high-tech enterprise investment and capital operation platform co-sponsored by Peking University alumni who have transformed achievements. Yanchuang Capital always takesvalue investment as the core, adhering to the corporate philosophy of "Integrity and character, customer-centered, and ultimate work", based on the excavation of China's outstanding achievements in the historical trend of economic growth, technological catch-up, and corporate growth. Enterprises and entrepreneurs; take capital as the main channel and provide empowerment services, and create greater value for investors through common growth and win-win development with outstanding enterprises and entrepreneurs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 37% |
| Health Care | 6 | 22% |
| Biopharma | 4 | 15% |
| Manufacturing | 4 | 15% |
| Pharmaceutical | 4 | 15% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 22% |
| Series B | 5 | 19% |
| Series C | 4 | 15% |
| Series D | 3 | 11% |
| Seed | 2 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 18 | 67% |
| United States | 2 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Weifan Intelligent | Weifan Intelligent is focused on the research and development of "big and small brain" integrated chips for embodied intelligence. | $14.9M | Seed | Aug 24, 2026 |  |
| Volant Aerotech | Volant Aerotech is a company specializing in the R&D, manufacturing, and service of passenger eVTOL, an electric vertical take-off and landing aircraft. |  | Series A | Dec 30, 2024 | http://www.volantaerotech.com |
| Volant Aerotech | Volant Aerotech is a company specializing in the R&D, manufacturing, and service of passenger eVTOL, an electric vertical take-off and landing aircraft. |  | Series A | Aug 19, 2024 | http://www.volantaerotech.com |
| Falcon Technology | Falcon Technology builds consumer-grade AR ecosystem and provides users with high-quality AR products and services. | $13.9M | Venture - Series Unknown | Mar 04, 2024 | https://xr.leiniao.com/ |
| Avistone Pharmaceuticals | Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics. | $140.7M | Series B | Dec 28, 2023 |  |
| Hongtu Semiconductor Technology | Hongtu Semiconductor Technology focuses on the CMOS image sensor chip design platform for producing CIS image sensors. | $13.9M | Seed | Aug 02, 2023 |  |
| uBriGene | Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization. | $14.7M | Series C | Dec 23, 2022 | http://www.ubrigene.com |
| TenNor Therapeutics | TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $9.5M | Series D | Dec 20, 2022 | http://www.tennorx.com/ |
| Laekna Therapeutics | Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development. Targeting large unmet medical needs, Laekna is dedicated to developing new therapies for cancer and liver diseases. | $61M | Series D | May 18, 2022 | http://www.laeknatp.com/ |
| TenNor Therapeutics | TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $41.6M | Series D | Mar 30, 2022 | http://www.tennorx.com/ |

10 of 27 investments shown.

## Co-investors
- [Beijing Robot Industry Fund](https://shizune.co/investors/profile/beijing-robot-industry-fund) — VC Fund, 3 deals together
- [Bain Capital](https://shizune.co/investors/profile/bain-capital) — VC Fund, 2 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 2 deals together
- [China Internet Investment Fund](https://shizune.co/investors/profile/china-internet-investment-fund) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [Dyee Capital](https://shizune.co/investors/profile/dyee-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Yanchuang Capital invest in?

Yanchuang Capital invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yanchuang Capital last invest?

The most recent investment recorded for Yanchuang Capital closed in Aug 2026. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co